Kenneth Gordon to Quality of Life
This is a "connection" page, showing publications Kenneth Gordon has written about Quality of Life.
Connection Strength
2.134
-
Deucravacitinib in moderate-to-severe psoriasis. Immunotherapy. 2022 11; 14(16):1279-1290.
Score: 0.466
-
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. J Eur Acad Dermatol Venereol. 2015 Apr; 29(4):767-76.
Score: 0.266
-
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023 10 28; 402(10412):1541-1551.
Score: 0.124
-
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021 12; 185(6):1146-1159.
Score: 0.107
-
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 02 06; 397(10273):475-486.
Score: 0.103
-
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. Am J Clin Dermatol. 2020 Dec; 21(6):881-890.
Score: 0.102
-
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. JAMA Dermatol. 2020 12 01; 156(12):1344-1353.
Score: 0.102
-
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020 06; 182(6):1348-1358.
Score: 0.096
-
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr; 80(4):1073-1113.
Score: 0.090
-
Treating to Target-A Realistic Goal in Psoriasis? Semin Cutan Med Surg. 2018 Feb; 37(2S):S44-S47.
Score: 0.084
-
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health. 2017 09; 20(8):1174-1179.
Score: 0.080
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-431.
Score: 0.078
-
Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016 Jul; 75(1):77-82.e7.
Score: 0.074
-
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014 Mar; 170(3):705-15.
Score: 0.064
-
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65.
Score: 0.049
-
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007; 18(6):341-50.
Score: 0.039
-
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005 May; 152(5):954-60.
Score: 0.035
-
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17; 290(23):3073-80.
Score: 0.031
-
Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology. 2021; 237(1):46-55.
Score: 0.024
-
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.
Score: 0.024
-
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018 Aug; 79(2):294-301.e6.
Score: 0.021
-
The experience of pain and redness in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2015 Oct; 26(5):401-5.
Score: 0.018
-
Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat. 2013 Aug; 24(4):255-60.
Score: 0.015
-
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012 Apr; 166(4):861-72.
Score: 0.014
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64.
Score: 0.011
-
The first World Psoriasis and Psoriatic Arthritis Conference. J Invest Dermatol. 2007 Jul; 127(7):1566-7.
Score: 0.010
-
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005 Jan; 141(1):31-8.
Score: 0.008